IMUC - ImmunoCellular Therapeutics Ltd(NYSEAMEX:IMUC)
- Creatore Discussione legolego
- Data di inizio
visal
In cul@ al nasdaq
- Registrato
- 20/6/01
- Messaggi
- 23.858
- Punti reazioni
- 304
Ho l'impressione che voglia sfondare il minimo odiernosono tentato...
mi raddoppio il numero di titoli vado a 2 di pmc
e chiudo il cassetto
maumal
Super Member
- Registrato
- 22/9/08
- Messaggi
- 2.596
- Punti reazioni
- 57
Stock Update:ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
By Melissa Bates · December 17, 2013
Last week, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) said that the company’s leading product-candidate, the dendritic cell-based vaccine that is used in brain cancer, did not show statistically significant advantage in the overall survival in the mid-stage study. This study also showed the differences of 2 months in median progression-free survival as well as the overall-survival favoring ICT-107 for all patients in that study. There were some differences in the median overall survival of 3 months in the arm of this study that received a minimum of 4 induction vaccinations.
Good report
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) believes that this data supports moving to the phase-III trial. The company expects to meet with the regulatory agencies in 2014Q4 and might start the phase III in 2015Q1 that may provide some topline data in 2018. The company’s stock dipped all of last week and in Monday’s trading session there was a drop of 10.91% and the shares closed at a price of $0.980 as the actual results of the study were not anywhere close to market expectations. Investors were hoping that the study would be able to reach its endpoint and the company would then file for approval
By Melissa Bates · December 17, 2013
Last week, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) said that the company’s leading product-candidate, the dendritic cell-based vaccine that is used in brain cancer, did not show statistically significant advantage in the overall survival in the mid-stage study. This study also showed the differences of 2 months in median progression-free survival as well as the overall-survival favoring ICT-107 for all patients in that study. There were some differences in the median overall survival of 3 months in the arm of this study that received a minimum of 4 induction vaccinations.
Good report
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) believes that this data supports moving to the phase-III trial. The company expects to meet with the regulatory agencies in 2014Q4 and might start the phase III in 2015Q1 that may provide some topline data in 2018. The company’s stock dipped all of last week and in Monday’s trading session there was a drop of 10.91% and the shares closed at a price of $0.980 as the actual results of the study were not anywhere close to market expectations. Investors were hoping that the study would be able to reach its endpoint and the company would then file for approval
maumal
Super Member
- Registrato
- 22/9/08
- Messaggi
- 2.596
- Punti reazioni
- 57
visal
In cul@ al nasdaq
- Registrato
- 20/6/01
- Messaggi
- 23.858
- Punti reazioni
- 304
Dai bella passa verde che e' troppo tempo che sei rossa
E poi sei in ipervenduta
maumal
Super Member
- Registrato
- 22/9/08
- Messaggi
- 2.596
- Punti reazioni
- 57
non ho capito se e' positivo e negativo... 
Why Northwest Bio's DCVax Brain Tumor Vaccine Will **** Up Just Like ImmunoCellular's ICT-107
BY Adam Feuerstein | 12/17/13 - 08:28 AM EST
Let's squash this silly notion that the blowup of ImmunoCellular Therapeutics' (IMUC_) dendritic brain tumor vaccine last week is an isolated incident without negative consequences for Northwest Biotherapeutics (NWBO_) and its nearly identical dendritic brain tumor vaccine.
I hate to break the bad news to Seeking Alpha contributor Josh Ginsburg, but Northwest's DCVax is not different from ImmunoCellular's ICT-107. DCVax will fail just like ICT-107 failed because dendritic cancer vaccines are too weak to overcome cancer's innate ability to overpower or evade the body's immune system.
The scientific community and most of Wall Street know this and have moved on from dendritic cancer vaccines. Today's buzz is antibody-based cancer immunotherapy -- the PD-1s and PDL-1s of Bristol-Myers Squibb (BMY_), Merck (MRK_), Roche (ROG_) and others which are showing incredible results in large clinical trials. A bit farther back but no less exciting is the work being done by academic researchers and Novartis (NVS_) with engineered T cells -- so-called CAR-T immunotherapy.
Last February, I explained in great detail why data from two early studies of Northwest Bio's DCVax in patients with glioblastoma multiforme (GBM) were sloppy, wrong and wildly misleading. Twenty GBM patients were handpicked for treatment with DCVax in these two phase I studies, so of course they outperformed expectations. The median progression-free survival of 26 months and median overall survival of 36 months touted by Northwest Bio as evidence of DCVax efficacy are not real. These DCVax data are a mirage which will vanish once Northwest Bio stops issuing endless promotional press releases and finally gets around to analyzing the much larger phase III study.
Seeking Alpha's Larry "Smith on Stocks" Smith was wrong about Northwest Bio last February and he's still wrong today when he whistles past ImmunoCellular's graveyard.
The bull thesis on ImmunoCellular's ICT-107 was also based on super-duper data from a small phase I study. Sixteen patients with newly diagnosed GBM were treated with ICT-107 at the prestigious Cedars-Sinai Medical Center in Los Angeles. The results were reportedly spectacular, including median overall survival of more than 38 months. Some ICT-107 patients were still alive five years after treatment. Historically, similar GBM patients enrolled in other, larger clinical trials only lived an average about 18 months, therefore ICT-107 be responsible for the prolonged survival benefit.
Um... no. Last week, ImmunoCellular announced negative results from its 124-patient phase II study of ICT-107 in GBM patients. Sure enough, the GBM patients treated with placebo lived about 18 months, as expected. The patients treated with ICT-107 survived only two months longer, on average.
What happened to the 38-month median overall survival data from the phase I study of ICT-107? Poof! Gone. A fantasy.
Don't expect any better outcome from Northwest Bio's DCVax.
Why Northwest Bio's DCVax Brain Tumor Vaccine Will **** Up Just Like ImmunoCellular's ICT-107
BY Adam Feuerstein | 12/17/13 - 08:28 AM EST
Let's squash this silly notion that the blowup of ImmunoCellular Therapeutics' (IMUC_) dendritic brain tumor vaccine last week is an isolated incident without negative consequences for Northwest Biotherapeutics (NWBO_) and its nearly identical dendritic brain tumor vaccine.
I hate to break the bad news to Seeking Alpha contributor Josh Ginsburg, but Northwest's DCVax is not different from ImmunoCellular's ICT-107. DCVax will fail just like ICT-107 failed because dendritic cancer vaccines are too weak to overcome cancer's innate ability to overpower or evade the body's immune system.
The scientific community and most of Wall Street know this and have moved on from dendritic cancer vaccines. Today's buzz is antibody-based cancer immunotherapy -- the PD-1s and PDL-1s of Bristol-Myers Squibb (BMY_), Merck (MRK_), Roche (ROG_) and others which are showing incredible results in large clinical trials. A bit farther back but no less exciting is the work being done by academic researchers and Novartis (NVS_) with engineered T cells -- so-called CAR-T immunotherapy.
Last February, I explained in great detail why data from two early studies of Northwest Bio's DCVax in patients with glioblastoma multiforme (GBM) were sloppy, wrong and wildly misleading. Twenty GBM patients were handpicked for treatment with DCVax in these two phase I studies, so of course they outperformed expectations. The median progression-free survival of 26 months and median overall survival of 36 months touted by Northwest Bio as evidence of DCVax efficacy are not real. These DCVax data are a mirage which will vanish once Northwest Bio stops issuing endless promotional press releases and finally gets around to analyzing the much larger phase III study.
Seeking Alpha's Larry "Smith on Stocks" Smith was wrong about Northwest Bio last February and he's still wrong today when he whistles past ImmunoCellular's graveyard.
The bull thesis on ImmunoCellular's ICT-107 was also based on super-duper data from a small phase I study. Sixteen patients with newly diagnosed GBM were treated with ICT-107 at the prestigious Cedars-Sinai Medical Center in Los Angeles. The results were reportedly spectacular, including median overall survival of more than 38 months. Some ICT-107 patients were still alive five years after treatment. Historically, similar GBM patients enrolled in other, larger clinical trials only lived an average about 18 months, therefore ICT-107 be responsible for the prolonged survival benefit.
Um... no. Last week, ImmunoCellular announced negative results from its 124-patient phase II study of ICT-107 in GBM patients. Sure enough, the GBM patients treated with placebo lived about 18 months, as expected. The patients treated with ICT-107 survived only two months longer, on average.
What happened to the 38-month median overall survival data from the phase I study of ICT-107? Poof! Gone. A fantasy.
Don't expect any better outcome from Northwest Bio's DCVax.
visal
In cul@ al nasdaq
- Registrato
- 20/6/01
- Messaggi
- 23.858
- Punti reazioni
- 304
visal
In cul@ al nasdaq
- Registrato
- 20/6/01
- Messaggi
- 23.858
- Punti reazioni
- 304
Io mi accontento anche di 2$a 4 stavolta esco
visal
In cul@ al nasdaq
- Registrato
- 20/6/01
- Messaggi
- 23.858
- Punti reazioni
- 304
Volumi in calopoi mi sembra un po' in ipervenduto... va be' che ha mancato l' ict-107 pero'...
Dovrà prima o poi rimbalzare
Si dovranno ricoprire gli shortisti e allora si che avremo una bella candela verde
visal
In cul@ al nasdaq
- Registrato
- 20/6/01
- Messaggi
- 23.858
- Punti reazioni
- 304
Gia in after sta a 0,76$Volumi in calo
Dovrà prima o poi rimbalzare
Si dovranno ricoprire gli shortisti e allora si che avremo una bella candela verde
MAzza che botte da orbi mi sa che taglio il cordone ombellicale
